Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis

Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma

(2013) Min Chen et al.   CLINICA CHIMICA ACTA

Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma

(2013) Min Yao et al.   Hepatobiliary & Pancreatic Diseases International

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis

(2012) Ying Zhou et al.   BMC CANCER

Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis

(2012) Caroline D. M. Witjes et al.   Hepatology International

Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma

(2011) Hasan Özkan et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma

(2010) Yilei Mao et al.   GUT

Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma

(2010) Eisuke Yasuda et al.   HEPATOLOGY RESEARCH

α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma

(2009) Jorge A. Marrero et al.   GASTROENTEROLOGY

Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma

(2009) Anna S. Lok et al.   GASTROENTEROLOGY

Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers

(2009) Pisit Tangkijvanich et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY